News
New PICCOLO trial analyses showed that mirvetuximab soravtansine achieved 52% response rates and 27-month overall survival in ...
DelveInsight’s Metastatic Prostate Cancer Pipeline report depicts a robust space with 80+ active players working to develop ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback